Generex Biotechnology Corporation, a leader in the area of buccal drug delivery, has launched Oral-lyn, the company's proprietary oral insulin spray product.

According to a Generex release, Oral-lyn is the first non-injectable form of recombinant human insulin available for commercial distribution anywhere in the world.

Oral-lyn is designed to improve the quality of life for patients with diabetes by allowing them to manage the disease more effectively. It is delivered by the company's proprietary RapidMist device into the mouth of the patient where it is absorbed with no lung deposition. Oral-lyn offers a safe, simple, convenient, fast, and effective alternative to prandial insulin injections.

Following equipment validation, Oral-lyn will be produced for commercial distribution at the manufacturing facilities of PharmaBRAND, the company's South American joint venture partner in Quito, Ecuador.

Oral-lyn, an aerosolised liquid insulin formulation, is rapidly and safely absorbed into the human body through the lining of the inner mouth (the buccal cavity) when delivered using the company's proprietary RapidMist device which resembles an asthma inhaler and is therefore nondescript and easy to use, added the release.

Generex is engaged in the research and development of drug delivery systems and technologies.